Sponsors

Sphere Fluidics updates branding

Sphere Fluidics, a company developing single-cell analysis systems underpinned by its patented picodroplet technology, has recently revealed its new branding to align with its ambitious global commercial growth strategy.

The update has been introduced to better reflect the company’s customer-centred approach and showcase its pioneering single-cell discovery and analysis technology, following a period of significant growth and programme success.

Sphere Fluidics’ range of novel cell encapsulation products for single cell analysis and isolation are aimed at easing customer workflows to accelerate scientific discovery. The company’s proprietary platform, Cyto-Mine, uses its picodroplet microfluidic technology and is capable of screening up to 40 million cells in several hours, while maintaining viability, to greatly increase throughput and support acceleration of biopharmaceutical discovery and development, cell therapy, and synthetic biology workflows. Sphere Fluidics’ core focus is on working with scientists to solve throughput challenges.

The company has seen a period of significant expansion over the last twelve months, including a series of new appointments within the senior leadership team, appointment of a new Chairman to the Board of Directors, expansion to its new facilities at Granta Park, Cambridge, UK, and the recent announcement of its involvement in the EU-funded research program, 3DSecret. 3DSecret is bringing together multidisciplinary experts to develop cutting-edge technologies to investigate the stochastic patterns behind metastasis at the single-cell level, to predict cancer evolution.

Dr Frank F Craig, CEO, Sphere Fluidics, commented: “We’re focused on transforming single-cell screening and isolation, working alongside customers to streamline their workflows. The rebrand signifies our ongoing commitment to growth, the strength of our position in the market as specialists in single cell analysis, and as providers of future-proof technology in this field.”

Find out more about Sphere Fluidics at www.spherefluidics.com.

 

Latest Issues

BIVDA Regulatory Affairs Seminar

Grand Hotel, Birmingham
10 - 11 February, 2026

BDIAP Molecular Pathology Study Day

10 Union Street, London, SE1 1SZ
2 March, 2026

Cell & Gene Therapy 2026

Hinxton Hall Conference Centre, Wellcome Genome Campus, Hinxton, CB10 1RQ
9-10 March, 2026